Advertisement

Pediatric Drugs

, Volume 7, Issue 1, pp 11–24 | Cite as

Toxic Shock Syndrome in Children

Epidemiology, Pathogenesis, and Management
  • Yu-Yu Chuang
  • Yhu-Chering HuangEmail author
  • Tzou-Yien Lin
Therapy In Practice

Abstract

Toxic shock syndrome (TSS) is an acute, toxin-mediated illness, like endotoxic shock, and is characterized by fever, rash, hypotension, multiorgan involvement, and desquamation. TSS reflects the most severe form of the disease caused by Staphylococcus aureus and Streptococcus pyogenes. A case definition for staphylococcal TSS was well established in the early 1980s and helped in defining the epidemiology. Since the late 1980s, a resurgence of highly invasive streptococcal infections, including a toxic shock-like syndrome, was noted worldwide and a consensus case definition for streptococcal TSS was subsequently proposed in 1993. Both TSS and the toxic shock-like syndrome occur at a lower incidence in children than in adults.

Changes in the manufacturing and use of tampons led to a decline in staphylococcal TSS over the past decade, while the incidence of nonmenstrual staphylococcal TSS increased. Nonmenstrual TSS and menstrual TSS are now reported with almost equal frequency. The incidence of streptococcal TSS remains constant after its resurgence, but varies with geographic location. Streptococcal TSS occurs most commonly following varicella or during the use of NSAIDs. Sites of infection in streptococcal TSS are much deeper than in staphylococcal TSS, such as infection caused by blunt trauma, and necrotizing fasciitis. Bacteremia is more common in streptococcal TSS than in staphylococcal TSS. Mortality associated with streptococcal TSS is 5–10% in children, much lower than in adults (30–80%), and is 3–5% for staphylococcal TSS in children.

TSS is thought to be a superantigen-mediated disease. Toxins produced by staphylococci and streptococci act as superantigens that can activate the immune system by bypassing the usual antigen-mediated immune-response sequence. The host-pathogen interaction, virulence factors, and the absence or presence of host immunity determines the epidemiology, clinical syndrome, and outcome.

Early recognition of this disease is important, because the clinical course is fulminant and the outcome depends on the prompt institution of therapy. Management of a child with TSS includes hemodynamic stabilization and appropriate antimicrobial therapy to eradicate the bacteria. Supportive therapy, aggressive fluid resuscitation, and vasopressors remain the main elements. An adjuvant therapeutic strategy may include agents that can block superantigens, such as intravenous immunoglobulin that contains superantigen neutralizing antibodies.

Keywords

Kawasaki Disease Necrotizing Fasciitis Toxic Shock Syndrome Scarlet Fever Streptococcal Toxic Shock Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Todd J, Fishaut M, Kapral F, et al. Toxic-shock syndrome associated with phagegroup 1 staphylococci. Lancet 1978; II: 1116–8CrossRefGoogle Scholar
  2. 2.
    Hoge CW, Schwartz B, Talkington DF, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: a retrospective population-based study. JAMA 1993; 269: 384–9PubMedCrossRefGoogle Scholar
  3. 3.
    The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993; 269: 390–1CrossRefGoogle Scholar
  4. 4.
    Reingold AL, Dan BB, Shands KN, et al. Toxic shock syndrome not associated with menstruation. Lancet 1982; I: 1–4CrossRefGoogle Scholar
  5. 5.
    Turner GR, Jackson MA, Levin DL, et al. Toxic shock syndrome in a 23-month-old male infant. Pediatr Infect Dis J 1983; 2: 314–6CrossRefGoogle Scholar
  6. 6.
    Wiesenthal AM, Todd JK. Toxic shock syndrome in children 10 years or less. Pediatrics 1984; 74: 112–7PubMedGoogle Scholar
  7. 7.
    Surh L, Read SE. Staphylococcal tracheitis and toxic shock syndrome in a young child. J Pediatr 1984; 105: 585–7PubMedCrossRefGoogle Scholar
  8. 8.
    Barbour SD, Shlaes DM, Guertin SR. Toxic shock syndrome associated with nasal packing: analogy to tampon-associated illness. Pediatrics 1984; 73: 163–5PubMedGoogle Scholar
  9. 9.
    Solomon R, Truman T, Murray DL. Toxic shock syndrome as a complication of bacterial tracheitis. Pediatr Infect Dis J 1985; 4: 298–9CrossRefGoogle Scholar
  10. 10.
    Frame JD, Eve MD, Hackett MEJ, et al. The toxic shock syndrome in burned children. Burns 1985; 11: 234–41CrossRefGoogle Scholar
  11. 11.
    Buchdahl R, Levin M, Wilkins B, et al. Toxic shock syndrome. Arch Dis Child 1985; 60: 563–7PubMedCrossRefGoogle Scholar
  12. 12.
    Chenaud M, Leclere F, Martinot A. Bacterial croup and toxic shock syndrome. Eur J Pediatr 1986; 145: 306–7PubMedCrossRefGoogle Scholar
  13. 13.
    Centers for Disease Control. Toxic shock syndrome associated with influenza: Minnesota. MMWR Morb Mortal Wkly Rep 1986; 35: 143–4Google Scholar
  14. 14.
    Centers for Disease Control. Toxic shock syndrome following influenza: Oregon. Update on influenza activity, United States. MMWR Morb Mortal Wkly Rep 1987; 36: 64–5Google Scholar
  15. 15.
    Sperber SJ, Francis JB. Toxic shock syndrome during an influenza outbreak. JAMA 1987; 257: 1086–7PubMedCrossRefGoogle Scholar
  16. 16.
    MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenza-like illness. JAMA 1987; 257: 1053–8PubMedCrossRefGoogle Scholar
  17. 17.
    Gruber WC, Pietsch JB. Toxic shock syndrome associated with Staphylococcus aureus enterocolitis. Pediatr Infect Dis J 1988; 7: 71–3PubMedCrossRefGoogle Scholar
  18. 18.
    Kline MW, Dunkle LM. Toxic shock syndrome and the acquired immunodeficiency syndrome. Pediatr Infect Dis J 1988; 7: 736–8PubMedCrossRefGoogle Scholar
  19. 19.
    McCarthy VP, Peoples WM. Toxic shock syndrome after ear piercing. Pediatr Infect Dis J 1988; 7: 741–2PubMedCrossRefGoogle Scholar
  20. 20.
    Tyson W, Wensley DF, Anderson JD, et al. Atypical staphylococcal toxic shock syndrome: two fatal pediatric cases. Pediatr Infect Dis J 1989; 8: 642–5PubMedCrossRefGoogle Scholar
  21. 21.
    Jacobson RM, Baltimore R. Toxic shock syndrome associated with osteomyelitis in premenarcheal girl. Pediatr Infect Dis J 1989; 8: 125–6PubMedGoogle Scholar
  22. 22.
    Heywood AJ, Essa SA. Toxic shock syndrome in child with only 2% burn [letter]. Lancet 1990; 335: 867PubMedCrossRefGoogle Scholar
  23. 23.
    Ferguson MA, Todd JK. Toxic shock syndrome associated with Staphylococcus aureus sinusitis in children. J Infect Dis 1990; 161: 953–5PubMedCrossRefGoogle Scholar
  24. 24.
    Cole RP, Shakespeare PG. Toxic shock syndrome in scalded children. Burns 1990; 16: 221–4PubMedCrossRefGoogle Scholar
  25. 25.
    Conway Jr EE, Haber RS, Gumprecht J, et al. Toxic shock syndrome following influenza A in a child. Crit Care Med 1991; 19: 123–5PubMedCrossRefGoogle Scholar
  26. 26.
    Tolan RW. Toxic shock syndrome complicating influenza A in a child: case report and review. Clin Infect Dis 1993; 17: 43–5PubMedCrossRefGoogle Scholar
  27. 27.
    Weinzweig J, Gottlieb LJ, Krizek TJ. Toxic shock syndrome associated with use of Biobrane® in a scald burn victim. Burns 1994; 20: 180–1PubMedCrossRefGoogle Scholar
  28. 28.
    Shah A, Moss W, Champion S, et al. Nonmenstrual toxic shock syndrome in a young child with human immunodeficiency virus infection. Pediatr Infect Dis J 1996; 15: 639–41PubMedCrossRefGoogle Scholar
  29. 29.
    Britto J, Habibi P, Walters S, et al. Systemic complications associated with bacterial tracheitis. Arch Dis Child 1996; 74: 249–50PubMedCrossRefGoogle Scholar
  30. 30.
    Davies HD, Kirk V, Jadavji T, et al. Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male. Pediatr Infect Dis J 1996; 15: 1136–8PubMedCrossRefGoogle Scholar
  31. 31.
    Van Lierde S, Leeuwen WJ, Ceuppens J, et al. Toxic shock syndrome without rash in a young child: link with syndrome of hemorrhagic shock and encephalopathy? J Pediatr 1997; 131: 130–4PubMedCrossRefGoogle Scholar
  32. 32.
    Fardy CH, Findlay G, Owen GO, et al. Toxic shock syndrome secondary to a dental abscess. Int J Oral Maxillofac Surg 1999; 28(1): 60–1PubMedCrossRefGoogle Scholar
  33. 33.
    Johnson D, Pathirana PDR. Toxic shock syndrome following cessation of prohylactic antibiotics in a child with a 2% scald. Burns 2002; 28: 181–4PubMedCrossRefGoogle Scholar
  34. 34.
    Wheeler MC, Roe MH, Kaplan EL, et al. Outbreak of group A Streptococcus septicemia in children: clinical, epidemiologic and microbiologic correlates. JAMA 1991; 266: 533–7PubMedCrossRefGoogle Scholar
  35. 35.
    Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr 1991; 1: 341–6Google Scholar
  36. 36.
    Jackson M, Burry V, Olson L. Multisystem group A beta-hemolytic streptococcal disease in children. Rev Infect Dis 1991; 13: 783–8PubMedCrossRefGoogle Scholar
  37. 37.
    Belani K, Schlivert P, Kaplan E, et al. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J 1991; 10: 351–4PubMedCrossRefGoogle Scholar
  38. 38.
    Holm S, Norrby A, Berholm A, et al. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988–1989. J Infect Dis 1992; 166: 32–6CrossRefGoogle Scholar
  39. 39.
    Torres-Martinez C, Mehta D, Butt A, et al. Streptococcus associated toxic shock. Arch Dis Child 1992; 67: 126–30PubMedCrossRefGoogle Scholar
  40. 40.
    Rathore M, Barton L, Kaplan E. Suppurative group A beta-hemolytic streptococcal infections in children. Pediatrics 1992; 89: 743–6PubMedGoogle Scholar
  41. 41.
    Floret D, Stamm D, Cochat P, et al. Streptococcal toxic shock syndrome in children. Intensive Care Med 1992; 18: 1–3CrossRefGoogle Scholar
  42. 42.
    Demers B, Simor A, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada, 1987–1991. Clin Infect Dis 1993; 16: 792–800PubMedCrossRefGoogle Scholar
  43. 43.
    Cowan MR, Primm PA, Scott SM, et al. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med 1994; 23: 818–23PubMedCrossRefGoogle Scholar
  44. 44.
    Davies HD, Matlow A, Scriver SR, et al. Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis J 1994; 13: 49–56PubMedCrossRefGoogle Scholar
  45. 45.
    Doctor A, Harper MB, Fleisher GR. Group A beta-hemolytic streptococcal bacteremia: historical overview, changing incidence and recent association with varicella. Pediatrics 1995; 96: 428–33PubMedGoogle Scholar
  46. 46.
    Brogan TV, Nizet V, Waldhausen JH, et al. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995; 14: 588–94PubMedCrossRefGoogle Scholar
  47. 47.
    Moses AE, Ziv A, Harai M, et al. Increased incidence and severity of Streptococcus pyogenes bacteremia in young children. Pediatr Infect Dis 1995; 14: 767–70CrossRefGoogle Scholar
  48. 48.
    Wilson GJ, Talkington DF, Gruber W, et al. Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. Clin Infect Dis 1995; 20: 1333–8PubMedCrossRefGoogle Scholar
  49. 49.
    Vugia D, Peterson CL, Meyers HB, et al. Invasive group A streptococcal infections in children with varicella in southern California. Pediatr Infect Dis J 1996; 15: 146–50PubMedCrossRefGoogle Scholar
  50. 50.
    Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996; 335: 547–54PubMedCrossRefGoogle Scholar
  51. 51.
    Chiobotaru P, Yagupsky P, Fraser D, et al. Changing epidemiology of invasive Streptococcus pyogenes infections in southern Israel: differences between two ethnic population groups. Pediatr Infect Dis J 1997; 16: 195–9PubMedCrossRefGoogle Scholar
  52. 52.
    Kiska DL, Thiede B, Caracciolo J, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 1997; 176: 992–1000PubMedCrossRefGoogle Scholar
  53. 53.
    Zurawski CA, Bardsley M, Beall B, et al. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis 1998; 27: 150–7PubMedCrossRefGoogle Scholar
  54. 54.
    Zerr DM, Alexander ER, Duchin JS, et al. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999; 103: 783–90PubMedCrossRefGoogle Scholar
  55. 55.
    Meza A, Gil H. Severe streptococcal infections and toxic shock in children. Int Pediatr 2000; 15: 232–5Google Scholar
  56. 56.
    Laupland KB, Davies H, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection: Ontario Group A Streptococcal Study Group. Pediatrics 2000; 105: E60PubMedCrossRefGoogle Scholar
  57. 57.
    Svensson N, Oberg S, Henriques B, et al. Invasive group A streptococcal infections in Sweden in 1994 and 1995: epidemiology and clinical spectrum. Scand J Infect Dis 2000; 32: 609–14PubMedCrossRefGoogle Scholar
  58. 58.
    Huang YC, Hsueh PR, Lin TY, et al. A family cluster of streptococcal toxic shock syndrome in children: clinical implication and epidemiological investigation. Pediatrics 2001; 107: 1181–3PubMedCrossRefGoogle Scholar
  59. 59.
    Huang YC, Huang YC, Chiu CH, et al. Characteristics of group A streptococcal bacteremia with comparison between children and adults. J Microbiol Immunol Infect 2001; 34: 195–200PubMedGoogle Scholar
  60. 60.
    Moses AE, Goldberg S, Korenman Z, et al. Invasive group A streptococcal infections: Israel. Emerg Infect Dis 2002; 8: 421–6PubMedCrossRefGoogle Scholar
  61. 61.
    O’Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995–1999. Clin Infect Dis 2002; 35: 268–76PubMedCrossRefGoogle Scholar
  62. 62.
    Watkins R, Vyas H. Toxic shock syndrome and streptococcal myositis: three case reports. Eur J Pediatr 2002; 161: 497–8PubMedCrossRefGoogle Scholar
  63. 63.
    Ben-Abraham R, Keller N, Vered R, et al. Invasive group A streptococcal infections in a large tertiary center: epidemiology, characteristics and outcome. Infection 2002; 30: 81–5PubMedCrossRefGoogle Scholar
  64. 64.
    Davies JP, Chesney PJ, Wand PJ, et al. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors and prevention. N Engl J Med 1980; 303: 1429–35CrossRefGoogle Scholar
  65. 65.
    Gaventa S, Reingold AL, Hightower AW, et al. Active surveillance for toxic shock syndrome in the United States: 1986. Rev Infect Dis 1989; 2Suppl. 1: S28–34CrossRefGoogle Scholar
  66. 66.
    Hajjeh RA, Reingold A, Weil A, et al. Toxic shock syndrome in the United States: surveillance update, 1979–1996. Emerg Infect Dis 1999; 5: 807–10PubMedCrossRefGoogle Scholar
  67. 67.
    Childs C, Jones VE, Dawson M, et al. Toxic shock syndrome toxin-1 (TSST-1) antibody level in burned children. Burns 1999; 25: 473–6PubMedCrossRefGoogle Scholar
  68. 68.
    Edwards-Jones V, Dawson MM, Childs C. A survey into toxic shock syndrome (TSS) in UK burn units. Burns 2000; 26: 323–33PubMedCrossRefGoogle Scholar
  69. 69.
    Stolz SJ, Davis JP, Vergeront JM, et al. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis 1985; 151: 883–9PubMedCrossRefGoogle Scholar
  70. 70.
    Graham GDR, O’Brien M, Hayes JM, et al. Postoperative toxic shock syndrome. Clin Infect Dis 1995; 20: 895–9PubMedCrossRefGoogle Scholar
  71. 71.
    Chesney JP, Davis JP. Toxic shock syndrome. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Philadelphia (PA): WB Saunders, 1998: 830–52Google Scholar
  72. 72.
    American Academy of Pediatrics Committee on Infectious Diseases. Severe invasive group A streptococcal infections: a subject review. Pediatrics 1998; 101: 136–40CrossRefGoogle Scholar
  73. 73.
    Schwartz A, Elliot JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992; 15: 277–84PubMedCrossRefGoogle Scholar
  74. 74.
    Gamba MA, Martinelli M, Schaad HJ, et al. Familial transmission of a serious disease-producing group A streptococcus clone: case report and review. Clin Infect Dis 1997; 24: 1118–21PubMedCrossRefGoogle Scholar
  75. 75.
    Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients: is prophylaxis warranted? JAMA 1998; 279: 1206–10CrossRefGoogle Scholar
  76. 76.
    Stevens DL. Streptococcal toxic shock syndrome. Clin Microbiol Infect 2002; 8: 133–6PubMedCrossRefGoogle Scholar
  77. 77.
    Murono K, Fujita K, Saijo M, et al. Emergence and spread of a new clone of M type 1 group A streptococcus coincident with the increase in invasive diseases in Japan. Pediatr Infect Dis J 1999; 18: 254–7PubMedCrossRefGoogle Scholar
  78. 78.
    Hsueh PR, Wu JJ, Tsai PJ, et al. Invasive group A streptococcal disease in Taiwan is not associated with the presence of streptococcal pyrogenic exotoxin genes. Clin Infect Dis 1998; 26: 584–9PubMedCrossRefGoogle Scholar
  79. 79.
    Stevens DL. Could nonsteroidal anti-inflammatory (NSAIDs) enhance the progression of bacterial infection? Clin Infect Dis 1995; 21: 977–80PubMedCrossRefGoogle Scholar
  80. 80.
    Barnham MR, Weightman NC, Anderson AW, et al. Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin Microbiol Infect 2002; 8: 174–81PubMedCrossRefGoogle Scholar
  81. 81.
    Manders S. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998; 39: 383–98PubMedCrossRefGoogle Scholar
  82. 82.
    Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2(3): 156–62PubMedCrossRefGoogle Scholar
  83. 83.
    Jardetzky TS, Brown JH, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility molecule complexed with superantigen. Nature 1993; 177: 175–84Google Scholar
  84. 84.
    Chatila T, Geha RS. Signal transduction by microbial superantigens via MHC class II molecules. Immunol Rev 1993; 131: 43–59PubMedCrossRefGoogle Scholar
  85. 85.
    Li H, Llera A, Malchiodi EL, et al. The structural basis of T-cell activation by superantigens. Annu Rev Immunol 1999; 17: 435–66PubMedCrossRefGoogle Scholar
  86. 86.
    McCormick J, Yarwood J, Schlievert P. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55: 77–104PubMedCrossRefGoogle Scholar
  87. 87.
    Schlievert PM, Shands KN, Dan BB, et al. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 1981; 143: 509–16PubMedCrossRefGoogle Scholar
  88. 88.
    Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13: 16–34PubMedCrossRefGoogle Scholar
  89. 89.
    Garbe PL, Arko RJ, Reingold AL, et al. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome: evidence for additional toxins. JAMA 1985; 253: 2538–42PubMedCrossRefGoogle Scholar
  90. 90.
    Waldvogel FA. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious disease. 5th ed. Vol. 2. New York (NY): Churchill Livingstone, 2000: 2069–92Google Scholar
  91. 91.
    Schlievert PM. Comparison of cotton and cotton/rayon tampons for effect on production of toxic shock syndrome toxin. J Infect Dis 1995; 172: 1112–4PubMedCrossRefGoogle Scholar
  92. 92.
    Wagner G, Bohr L, Wagner P, et al. Tampon-induced changes in vaginal oxygen and carbon dioxide tensions. Am J Obstet Gynecol 1984; 148: 147–5PubMedGoogle Scholar
  93. 93.
    Stevens DL. Toxic shock syndromes. Infect Dis Clin North Am 1996; 10(4): 727–46PubMedCrossRefGoogle Scholar
  94. 94.
    Stevens DL. The flesh-eating bacterium: what’s next? J Infect Dis 1999; 179Suppl. 2: S366–74PubMedCrossRefGoogle Scholar
  95. 95.
    Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis and new concepts in treatment. Emerg Infect Dis 1995; 1: 69–78PubMedCrossRefGoogle Scholar
  96. 96.
    McCormick JK, Pragman AA, Stolpa JC, et al. Functional characterization of streptococcal pyrogenic exotoxin J, a novel superantigen. Infect Immun 2001; 69: 1381–8PubMedCrossRefGoogle Scholar
  97. 97.
    Brown EJ. The molecular basis of streptococcal toxic shock syndrome. N Engl J Med 2004; 350: 2093–4PubMedCrossRefGoogle Scholar
  98. 98.
    Herwald H, Cramer H, Morgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004; 116: 367–79PubMedCrossRefGoogle Scholar
  99. 99.
    Vergeront J, Stolz SJ, Crass BA, et al. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic shock syndrome. J Infect Dis 1983; 148: 692–8PubMedCrossRefGoogle Scholar
  100. 100.
    Erikson BK, Anderson J, Holm SE, et al. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 1999; 180: 410–8CrossRefGoogle Scholar
  101. 101.
    Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8: 1398–404PubMedCrossRefGoogle Scholar
  102. 102.
    American Academy of Pediatrics. Toxic shock syndrome. In Pickering LK, editor. 2000 red book: report of the committee on infectious diseases. 25th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2000: 576–81Google Scholar
  103. 103.
    Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public surveillance. MMWR Recomm Rep 1990; 39(RR-13): 1–43PubMedGoogle Scholar
  104. 104.
    Kain KC, Schulzer M, Chow AW. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 1993; 16: 100–6PubMedCrossRefGoogle Scholar
  105. 105.
    Andrews MM, Parent EM, Barry M, et al. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis and treatment. Clin Infect Dis 2001; 32: 1470–9PubMedCrossRefGoogle Scholar
  106. 106.
    Parsonnet J, Modern PA, Giacobbe K. Effect of subinhibitory concentrations of antibiotics on production of toxic shock syndrome toxin-1 (TSST-1) [abstract]. Program and abstracts of the 32nd meeting of the Infectious Disease Society of America; 1994 Oct 7–9; OrlandoGoogle Scholar
  107. 107.
    Stevens DL, Gibbons AE, Bergstrom R, et al. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158: 23–8PubMedCrossRefGoogle Scholar
  108. 108.
    Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production and host response. Clin Infect Dis 1995; 20Suppl. 2: S154–7PubMedCrossRefGoogle Scholar
  109. 109.
    Schlievert P. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001; 108: S107–10PubMedCrossRefGoogle Scholar
  110. 110.
    Barry W, Hudgins L, Donta ST, et al. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267: 3315–6PubMedCrossRefGoogle Scholar
  111. 111.
    Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999; 28: 800–7PubMedCrossRefGoogle Scholar
  112. 112.
    Norrby-Teglund A, Basma H, Anderson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26: 631–8PubMedCrossRefGoogle Scholar
  113. 113.
    Darenberg J, Soderquist B, Normark BH, et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38: 836–42PubMedCrossRefGoogle Scholar
  114. 114.
    Dalton HJ. Recombinant activated protein C in pediatric sepsis. Pediatr Infect Dis J 2003; 22(8): 743–5PubMedCrossRefGoogle Scholar
  115. 115.
    Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348(2): 138–50PubMedCrossRefGoogle Scholar
  116. 116.
    Roggiani M, Stoehr J, Olmsted S, et al. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 2000; 68: 5011–7PubMedCrossRefGoogle Scholar
  117. 117.
    McCormick J, Tripp T, Olmsted S, et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in rabbit model of toxic shock syndrome. J Immunol 2000; 165: 2306–12PubMedGoogle Scholar
  118. 118.
    Visvanathan K, Charles A, Bannan J, et al. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immunol 2001; 69: 875–84CrossRefGoogle Scholar
  119. 119.
    Arad G, Levy R, Hillman D, et al. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6: 414–21PubMedCrossRefGoogle Scholar
  120. 120.
    Kum WW, Laupland KB, Chow AW. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 2000; 46: 171–9PubMedCrossRefGoogle Scholar
  121. 121.
    Pang LT, Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin Binduced lymphocyte proliferation and tumor necrosis factor-α secretion by MAb5, an anti-toxic shock syndrome toxin-1 monoclonal antibody. Infect Immun 2000; 68: 3261–8PubMedCrossRefGoogle Scholar
  122. 122.
    Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1. J Infect Dis 2001; 183: 1739–48PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Yu-Yu Chuang
    • 1
  • Yhu-Chering Huang
    • 2
    Email author
  • Tzou-Yien Lin
    • 2
  1. 1.Department of PediatricsSt. Mary’s HospitalLoTungTaiwan
  2. 2.Division of Pediatric Infectious DiseasesChang Gung Children’s HospitalTaoyuanTaiwan

Personalised recommendations